Patient and disease characteristics
. | Marrow . | G-PBMC . | Overall . |
|---|---|---|---|
| Patient no. | 18 | 71 | 89 |
| Median age, y | 52.5 | 53 | 53 |
| Median no. of preceding therapies (range) | 4 (0-12) | 4 (0-11) | 4 (0-12) |
| Median follow-up after HCT, d | 425 | 390 | 390 |
| Preceding auto/allo HCT | 4/2 | 19/2 | 23/4 |
| Median no. CD34 cells × 106/kg (range) | 2.1 (0.21-4.1) | 7.0 (1.26-28) | 5.72 (0.21-28) |
| Median no. CD3 × 108/kg | 0.3 | 2.6 | 2.33 |
| Donor HLA match, no. of patients | |||
| 10 allele match | 15 | 54 | 69 |
| 1 class l allele mismatch | 3 | 13* | 16 |
| Diagnosis and status at HCT, no. of patients | |||
| AML/ALL, total | 4 | 13 | 17 |
| CR1 | 2 | 6 | 8 |
| CR2 | 2 | 2 | 4 |
| More than CR3 | 0 | 4 | 4 |
| Rel/ref/IF | 0 | 1 | 1 |
| MDS, total | 4 | 17 | 21 |
| RA | 1 | 3 | 4 |
| RAEB | 1 | 2 | 3 |
| RAEB-T | 0 | 3 | 3 |
| AML CR1/CR2 | 0/0 | 2/1 | 3 |
| AML Rel/ref | 0/2 | 2/1 | 2/3 |
| CMML PR/ref/IF | 0/0/0 | 1/1/1 | 1/1/1 |
| CML, total | 4 | 10 | 14 |
| CP/AP/BP | 2/1/1 | 6/1/0 | 8/2/1 |
| CP-2 | 0 | 3 | 3 |
| MPS, total | 2 | 5 | 7 |
| ET | 0 | 2 | 2 |
| AMM-transformation | 2 | 1 | 3 |
| NOS | 0 | 2 | 2 |
| Indolent/high-grade NHL, total | 3 | 10 | 13 |
| CR 3 | 0 | 2 | 2 |
| PR | 1 | 2 | 3 |
| Ref/rel | 0/2 | 4/2 | 4/4 |
| CLL, total | 0 | 5 | 5 |
| CR | 0 | 1 | 1 |
| FLU refractory | 0 | 4 | 4 |
| HD, total | 0 | 4 | 4 |
| PR | 0 | 2 | 2 |
| Rel | 0 | 2 | 2 |
| MM, total | 0 | 7 | 7 |
| PR/ref | 0 | 4/3 | 4/3 |
| Waldenstroms, total | 1 | 0 | 1 |
. | Marrow . | G-PBMC . | Overall . |
|---|---|---|---|
| Patient no. | 18 | 71 | 89 |
| Median age, y | 52.5 | 53 | 53 |
| Median no. of preceding therapies (range) | 4 (0-12) | 4 (0-11) | 4 (0-12) |
| Median follow-up after HCT, d | 425 | 390 | 390 |
| Preceding auto/allo HCT | 4/2 | 19/2 | 23/4 |
| Median no. CD34 cells × 106/kg (range) | 2.1 (0.21-4.1) | 7.0 (1.26-28) | 5.72 (0.21-28) |
| Median no. CD3 × 108/kg | 0.3 | 2.6 | 2.33 |
| Donor HLA match, no. of patients | |||
| 10 allele match | 15 | 54 | 69 |
| 1 class l allele mismatch | 3 | 13* | 16 |
| Diagnosis and status at HCT, no. of patients | |||
| AML/ALL, total | 4 | 13 | 17 |
| CR1 | 2 | 6 | 8 |
| CR2 | 2 | 2 | 4 |
| More than CR3 | 0 | 4 | 4 |
| Rel/ref/IF | 0 | 1 | 1 |
| MDS, total | 4 | 17 | 21 |
| RA | 1 | 3 | 4 |
| RAEB | 1 | 2 | 3 |
| RAEB-T | 0 | 3 | 3 |
| AML CR1/CR2 | 0/0 | 2/1 | 3 |
| AML Rel/ref | 0/2 | 2/1 | 2/3 |
| CMML PR/ref/IF | 0/0/0 | 1/1/1 | 1/1/1 |
| CML, total | 4 | 10 | 14 |
| CP/AP/BP | 2/1/1 | 6/1/0 | 8/2/1 |
| CP-2 | 0 | 3 | 3 |
| MPS, total | 2 | 5 | 7 |
| ET | 0 | 2 | 2 |
| AMM-transformation | 2 | 1 | 3 |
| NOS | 0 | 2 | 2 |
| Indolent/high-grade NHL, total | 3 | 10 | 13 |
| CR 3 | 0 | 2 | 2 |
| PR | 1 | 2 | 3 |
| Ref/rel | 0/2 | 4/2 | 4/4 |
| CLL, total | 0 | 5 | 5 |
| CR | 0 | 1 | 1 |
| FLU refractory | 0 | 4 | 4 |
| HD, total | 0 | 4 | 4 |
| PR | 0 | 2 | 2 |
| Rel | 0 | 2 | 2 |
| MM, total | 0 | 7 | 7 |
| PR/ref | 0 | 4/3 | 4/3 |
| Waldenstroms, total | 1 | 0 | 1 |
G-PBMC indicates granulocyte colony-stimulating factor—mobilized peripheral blood mononuclear cells; HCT, hematopoietic cell transplantation; auto, autologous; allo, allogeneic; AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; CR, complete remission; rel, relapsed; ref, refractory; IF, induction failure; MDS, myelodysplastic syndromes; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-T, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; PR, partial remission; CML, chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase; BP, blast phase; MPS, myeloproliferative syndromes; ET, essential thrombocytosis; AMM transformation, agnogeneic myeloid metaplasia in transformation; NOS, not otherwise specified; NHL, non-Hodgkin lymphoma; CLL, chronic lymphoid leukemia; FLU, fludarabine; HD, Hodgkin disease; and MM, multiple myeloma.
One patient mismatched at 3 class l alleles.